search
Back to results

Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Colesevelam hydrochloride
placebo
Sponsored by
Daiichi Sankyo, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Subjects meeting the following criteria at the Screening Visit will be eligible to participate in the trial: Have given written informed consent Ages 18 to 75 years, inclusive Diagnosis of type 2 diabetes mellitus of at least 3 months duration HbA1C 7.0- 10.0%, inclusive Antidiabetic treatment may include oral agents; all antidiabetic agents must be withdrawn before randomization Women may be enrolled if they are not pregnant (negative serum βHCG at the Screening Visit), are not breast-feeding, and do not plan to become pregnant during the trial. In addition, they must either have had a hysterectomy or tubal ligation at least 6 months before signing informed consent, be post-menopausal for 1 year, or practicing an acceptable method of birth control. An acceptable method of birth control may be oral, injectable or implantable hormonal contraceptives, intrauterine device, diaphragm plus spermicide, or female condom plus spermicide. Abstinence, partner's use of condoms, and partner's vasectomy are NOT acceptable methods of contraception BMI 25 - 45 kg/M sq, inclusive Exclusion Criteria: Subjects are excluded from participation in the study if any of the following criteria apply: Type 1 diabetes mellitus or history of diabetic ketoacidosis Treatment with lipid or blood pressure lowering therapy that has not been stable for three months before randomization Treatment with WelChol, cholestyramine or colestipol for hyperlipidemia within the last 3 months Treatment with thiazolidinediones History of dysphagia, swallowing disorders, or intestinal motility disorder Serum triglyceride >500 mg/dL at Visit 1 Serum LDL-C <60 mg/dL at Visit 1 Any condition or therapy which, in the opinion of the investigator, poses a risk to the subject or makes participation not in the subject's best interest Use of any investigational drug within 30 days before randomization Chronic treatment with oral corticosteroids History of hyperthyroidism and/or treatment with thyroid hormone/ levothyroxine

Sites / Locations

  • Diabetes and Glandular Research Associates

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

1

2

Arm Description

Colesevelam hydrochloride

placebo

Outcomes

Primary Outcome Measures

To evaluate the effect of 8 weeks treatment with WelChol on insulin sensitivity,as measured by the hyperinsulinemic-euglycemic clamp method, i.e., placebo-corrected change from baseline in M-value.

Secondary Outcome Measures

To evaluate the effect of 2 weeks treatment with WelChol on insulin sensitivity,as measured by the hyperinsulinemic-euglycemic clamp method.
To evaluate acute and chronic effects of treatment with WelChol on plasma glucose after ingestion of a standard meal replacement.
To evaluate the effect of treatment with WelChol on HbA1C, insulin, fasting plasma glucose, and fructosamine.

Full Information

First Posted
August 3, 2006
Last Updated
June 24, 2008
Sponsor
Daiichi Sankyo, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00361153
Brief Title
Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus
Official Title
Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
June 2008
Overall Recruitment Status
Completed
Study Start Date
May 2006 (undefined)
Primary Completion Date
October 2006 (Actual)
Study Completion Date
March 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Daiichi Sankyo, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is designed to test whether WelChol (colesevelam HC1) improves blood sugar control in patients with type 2 diabetes by making their own insulin work more efficiently.
Detailed Description
Single-center, randomized, parallel, double-blind, placebo controlled, 8-week trial in subjects with type 2 diabetes mellitus. Two parallel treatment groups include double-blind colesevelam or placebo. A screening period may be up to 18 weeks to withdraw non sulfonylurea antidiabetic treatment or withdraw or adjust sulfonylurea antidiabetic treatment. To evaluate hepatic and peripheral insulin sensitivity, subjects will undergo a two-step hyperinsulinemic-euglycemic clamp with a tritiated glucose infusion at pre randomization and after 8 weeks of treatment. To evaluate oral glucose absorption, subjects will undergo two oral glucose tolerance tests (OGTT) at pre randomization, one without colesevelam and one with colesevelam, and one OGTT at the end of the treatment period..

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
35 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
Colesevelam hydrochloride
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
placebo
Intervention Type
Drug
Intervention Name(s)
Colesevelam hydrochloride
Other Intervention Name(s)
Welchol
Intervention Description
Welchol tablet 625mg
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
placebo
Primary Outcome Measure Information:
Title
To evaluate the effect of 8 weeks treatment with WelChol on insulin sensitivity,as measured by the hyperinsulinemic-euglycemic clamp method, i.e., placebo-corrected change from baseline in M-value.
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
To evaluate the effect of 2 weeks treatment with WelChol on insulin sensitivity,as measured by the hyperinsulinemic-euglycemic clamp method.
Time Frame
2 weeks
Title
To evaluate acute and chronic effects of treatment with WelChol on plasma glucose after ingestion of a standard meal replacement.
Time Frame
8 weeks
Title
To evaluate the effect of treatment with WelChol on HbA1C, insulin, fasting plasma glucose, and fructosamine.
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects meeting the following criteria at the Screening Visit will be eligible to participate in the trial: Have given written informed consent Ages 18 to 75 years, inclusive Diagnosis of type 2 diabetes mellitus of at least 3 months duration HbA1C 7.0- 10.0%, inclusive Antidiabetic treatment may include oral agents; all antidiabetic agents must be withdrawn before randomization Women may be enrolled if they are not pregnant (negative serum βHCG at the Screening Visit), are not breast-feeding, and do not plan to become pregnant during the trial. In addition, they must either have had a hysterectomy or tubal ligation at least 6 months before signing informed consent, be post-menopausal for 1 year, or practicing an acceptable method of birth control. An acceptable method of birth control may be oral, injectable or implantable hormonal contraceptives, intrauterine device, diaphragm plus spermicide, or female condom plus spermicide. Abstinence, partner's use of condoms, and partner's vasectomy are NOT acceptable methods of contraception BMI 25 - 45 kg/M sq, inclusive Exclusion Criteria: Subjects are excluded from participation in the study if any of the following criteria apply: Type 1 diabetes mellitus or history of diabetic ketoacidosis Treatment with lipid or blood pressure lowering therapy that has not been stable for three months before randomization Treatment with WelChol, cholestyramine or colestipol for hyperlipidemia within the last 3 months Treatment with thiazolidinediones History of dysphagia, swallowing disorders, or intestinal motility disorder Serum triglyceride >500 mg/dL at Visit 1 Serum LDL-C <60 mg/dL at Visit 1 Any condition or therapy which, in the opinion of the investigator, poses a risk to the subject or makes participation not in the subject's best interest Use of any investigational drug within 30 days before randomization Chronic treatment with oral corticosteroids History of hyperthyroidism and/or treatment with thyroid hormone/ levothyroxine
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Director Clinical Development
Organizational Affiliation
Daiichi Sankyo, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Diabetes and Glandular Research Associates
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
20059361
Citation
Schwartz SL, Lai YL, Xu J, Abby SL, Misir S, Jones MR, Nagendran S. The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study. Metab Syndr Relat Disord. 2010 Apr;8(2):179-88. doi: 10.1089/met.2009.0049.
Results Reference
derived

Learn more about this trial

Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus

We'll reach out to this number within 24 hrs